First Results from the ENGOT-GYN2/ GOG-3051/BOUQUET Phase II Biomarker-Directed Platform Study: Cobimetinib (Cobi) Or Atezolizumab (Atezo) Plus Bevacizumab (Bev) for Persistent/Recurrent Rare Epithelial Ovarian Cancer (Eoc)

No Thumbnail Available

Date

2023

Authors

Journal Title

Journal ISSN

Volume Title

Publisher

Abstract

Description

Keywords

Citation

URI

http://hdl.handle.net/11727/12121

Collections

Tıp Fakültesi / Faculty of Medicine

Endorsement

Review

Supplemented By

Referenced By